Abstract
Interleukin (IL)-18 is a proinflammatory cytokine which plays a crucial role in T helper (Th)1 type immune response. The aim of this study is to investigate the relationship of serum levels of IL-18 with disease activity and clinical presentations in patients with Behcet’s disease (BD). Sixty patients with BD and 20 healthy controls were included in the study. Patients were grouped as having active or inactive disease according to the Leeds activity score. They were also separated as a systemic involvement or mucocutaneous symptoms only. Patients with systemic involvement were further grouped according to the presence of ocular, articular and vascular involvement. IL-18 levels were significantly higher in all patient subgroups as compared to healthy controls and found to be correlated with the activity score in patients having active disease. In conclusion, this cytokine participates in the pathogenesis of BD and its levels are correlated with the disease activity. Detection of increased levels of IL-18 in patients with inactive disease implies that Th1 activation and subclinical inflammation persist during the inactive period of the disease.
References
Liew FY, McInnes IB (2002) Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 61:100–102
Liew FY, Wei XQ, McInnes IB (2003) Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis 62:48–50
Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275–285
Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474
Dinerallo CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20(suppl27):S1–S13
Gracie JA, Robertson SE, McInnes IB (2003) Interleukin-18. J Leukoc Biol 73: 213–224
Matsui K, Tsutsui H, Nakanishi K (2003) Pathophysiological roles for IL-18 in inflammatory arthritis. Expert Opin Ther Targets 7:701–724
Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, Cunha F, Liew FY, McInnes IB (2001) A role for IL-18 in neutrophil activation. J Immunol 167: 2879–2886
Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, Barrera P, van den Berg WB (2003) Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 48:339–347
Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K (2004) Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 50:432–443
Morel JC, Park CC, Kumar P, Koch AE (2001) Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest 81:1371–1383
Komai-Koma M, Gracie JA, Wei XQ, Xu D, Thomson N, McInnes IB, Liew FY (2003) Chemoattraction of human T cells by IL-18. J Immunol 170:1084–1090
Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE (2001) Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167:1644–1653
Futani H, Okayama A, Matsui K, Kashiwamura S, Sasaki T, Hada T, Nakanishi K, Tateishi H, Maruo S, Okamura H (2002) Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. J Immunother 25(Suppl1):S61–S64
Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K, Kakishita E (2000) Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 109:652–657
Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum 44:550–560
Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis 63:1300–1306
Behçet H (1937) Uber rezidivierende apthose, durch ein virus verursachte geschwure am mund, am auge und an den genitalien. Dermatol Wochenschr 105:1152–1157
Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Behcet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42:1967–1974
Alpsoy E, Cayirli C, Er H, Yilmaz E (1998) The levels of plasma interleukin-2 and soluble interleukin-2R in Behcet’s disease: a marker of disease activity. J Dermatol 25:513–516
Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K (2002) Cytokine profile in Behcet’s disease patients. Relationship with disease activity. Scand J Rheumatol 31:205–210
Ohno S, Kato F, Matsuda H, Fujii N, Minagawa T (1982) Detection of gamma interferon in the sera of patients with Behcet’s disease. Infect Immun 36:202–208
Ohno S, Kato F, Matsuda H, Fujii N, Minagawa T (1982) Studies on spontaneous production of gamma-interferon in Behcet’s disease. Ophthalmologica 185:187–192
Bacon TH, Ozbakir F, Elms CA, Denman AM (1984) Interferon-gamma production by peripheral blood mononuclear cells from patients with Behcet’s syndrome. Clin Exp Immunol 57:541–547
Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M (1998) Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet’s disease. Invest Ophthalmol Vis Sci 39:996–1004
Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S (1998) Divergent cytokine production profile in Behcet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 25:329–333
Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S (2003) Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behcet’s disease. J Dermatol 30:602–607
Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S (1996) Cytokines in Behcet’s disease. J Rheumatol 23:321–322
Hamzaoui K, Hamza M, Ayed K (1990) Production of TNF-alpha and IL-1 in active Behcet’s disease. J Rheumatol 17:1428–1429
Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanc M, Capo C (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549
Hamzaoui A, Ghrairi H, Ammar J, Zekri S, Guemira F, Hamzaoui K (2003) IL-18 mRNA expression and IFN-gamma induction in bronchoalveolar lavage from Behcet’s disease. Clin Exp Rheumatol 21(Suppl30):S8–S14
International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080
Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behcet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38:728–733
Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B (2005) Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet’s disease. Clin Exp Dermatol 30:61–63
Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A (2003) Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet’s disease. Rheumatolgy 42:860–864
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Musabak, U., Pay, S., Erdem, H. et al. Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations?. Rheumatol Int 26, 545–550 (2006). https://doi.org/10.1007/s00296-005-0029-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-005-0029-8